Liontrust Investment Partners LLP Sells 6,111 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Liontrust Investment Partners LLP cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 32.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,769 shares of the biopharmaceutical company’s stock after selling 6,111 shares during the quarter. Liontrust Investment Partners LLP’s holdings in Alnylam Pharmaceuticals were worth $4,164,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. SVB Wealth LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter worth approximately $27,000. Atlantic Union Bankshares Corp purchased a new stake in Alnylam Pharmaceuticals in the second quarter worth $30,000. Elevation Point Wealth Partners LLC purchased a new stake in Alnylam Pharmaceuticals in the second quarter worth $37,000. Ameritas Advisory Services LLC bought a new stake in Alnylam Pharmaceuticals in the second quarter valued at $42,000. Finally, AlphaQuest LLC purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at $43,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 3.7%

Shares of Alnylam Pharmaceuticals stock opened at $397.55 on Monday. The company has a 50-day simple moving average of $452.35 and a two-hundred day simple moving average of $408.12. The stock has a market capitalization of $52.52 billion, a PE ratio of 1,656.46 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54.

Wall Street Analyst Weigh In

ALNY has been the subject of several research analyst reports. Citigroup raised their target price on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the stock a “buy” rating in a research report on Tuesday, September 2nd. Piper Sandler restated an “overweight” rating and set a $489.00 price target (up from $449.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Royal Bank Of Canada upped their price target on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a research note on Friday, September 19th. Wall Street Zen raised Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 10th. Finally, Barclays boosted their target price on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Twenty-three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $482.71.

Insiders Place Their Bets

In other news, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the company’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $452.18, for a total transaction of $5,484,039.04. Following the transaction, the executive vice president directly owned 21,264 shares of the company’s stock, valued at $9,615,155.52. This represents a 36.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Yvonne Greenstreet sold 15,650 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $453.69, for a total value of $7,100,248.50. Following the sale, the chief executive officer directly owned 65,409 shares in the company, valued at $29,675,409.21. This trade represents a 19.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 60,328 shares of company stock worth $27,288,993 in the last three months. Corporate insiders own 1.20% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.